Objective-To verify that adiponectin and tumor necrosis factor (TNF)-␣ reciprocally regulate their expression, thereby synergistically affecting both coronary and aortic endothelial dysfunction in type 2 diabetic mice. Methods and Results-We examined endothelium-dependent and endothelium-independent vasodilation/vasorelaxation of coronary arterioles and aortas in control mice, diabetic mice (Lepr db ), and Lepr db treated with adiponectin or neutralizing antibody to TNF-␣ (anti-TNF-␣). Endothelium-dependent vasodilation to acetylcholine in both coronary arterioles and aortas was blunted in Lepr db compared with control mice. Endothelium-independent vasodilation to sodium nitroprusside was comparable. Adiponectin and anti-TNF-␣ improved acetylcholine-induced vasodilation of coronary arterioles and aortas in Lepr db without affecting dilator response to sodium nitroprusside. Adiponectin protein expression was significantly reduced, and TNF-␣ protein expression was significantly greater, in coronary arterioles and aortas of Lepr db compared with control mice. Immunofluorescence staining results indicate that adiponectin was colocalized with endothelial cells. Anti-TNF-␣ treatment upregulated adiponectin protein expression in Lepr db coronary arterioles and aortas. Adiponectin administration reduced TNF-␣ protein expression in Lepr db . Although adiponectin receptor 1 protein expression in coronary arterioles and aortas was similar between control and diabetic mice, adiponectin receptor 2 protein expression was significantly reduced in Lepr db . Both adiponectin and anti-TNF-␣ inhibited IB␣ phosphorylation and nuclear factor B protein expression in Lepr db , suggesting that adiponectin and TNF-␣ signaling may converge on nuclear factor B to reciprocally regulate their expression. 
T he growing epidemic of cardiovascular disease in developed countries is closely associated with increased prevalence of obesity and type 2 diabetes mellitus. 1, 2 Much of the recent work on obesity 3 has highlighted the key role of adipose tissue as an endocrine organ that secretes several factors, termed adipokines, that mediate many of the vascular and metabolic complications of obesity. An adverse adipokine expression profile, characterized by diminished production of protective factors (eg, adiponectin) and increased detrimental adipokines (eg, tumor necrosis factor [TNF]-␣), has been suggested in obese and type 2 diabetic patients. 4 -7 Adiponectin, also known as ACRP30 or AdipoQ, is an adipokine that is secreted from adipocytes. 8 Adiponectin plays an important role in the regulation of glucose and lipid metabolism. 9 Paradoxically, the serum concentration of adiponectin is decreased in obese and type 2 diabetic patients despite increased adiposity. 10 In contrast, plasma TNF-␣ levels are elevated in such patients, suggesting that there may be an imbalance between the production of adiponectin and TNF-␣ in obesity. 11 In 3T3-L1 adipocytes, decreased adiponectin mRNA levels by TNF-␣ were partially recovered by treatment with a c-JUN N-terminal kinase inhibitor, suggesting that the c-JUN N-terminal kinase signaling pathway, activated by TNF-␣, is involved in the regulation of adiponectin expression in adipocytes. 7 Another study 12 shows that adiponectin decreases leptin-induced TNF-␣ expression by murine macrophages through suppression of phosphorylation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase pathways. Thus, there may be a reciprocal association between adiponectin and TNF-␣.
Adipose-derived adipokines actively participate in the regulation of vascular function (ie, TNF-␣ contributes to the impairment of coronary and aortic vascular function in type 2 diabetic mice). 13, 14 However, the following issues have not been resolved: (1) the role of adiponectin in regulating coronary and aortic vascular function in type 2 diabetic mice and (2) whether there is a reciprocal association between adiponectin and TNF-␣. Thus, the goal of this study was to examine the nature and mechanisms of putative reciprocal suppressive effects between adiponectin and TNF-␣ in coronary microvessels and aortas in type 2 diabetic mice and how this reciprocal regulation can contribute to the pathogenesis of diabetes-associated vascular dysfunction.
Methods

Animals
The procedures followed were in accordance with approved guidelines set by the Laboratory Animal Care Committee at the University of Missouri. 
Functional Assessment of Isolated Coronary Arterioles
The techniques for identification and isolation of coronary microvessels were described in detail previously. 13 Coronary arterioles, 40-to 100-m diameter, from mouse heart were carefully dissected for in vitro study. To determine whether adiponectin plays a role in vascular dysfunction in type 2 diabetes, vasodilation to endothelium-dependent vasodilator acetylcholine (ACh), 0.1 nmol/L to 10 mol/L; endothelium-independent vasodilator sodium nitroprusside (SNP), 0.1 nmol/L to 10 mol/L; or flow-induced dilation (NO mediated and endothelium dependent but agonist independent), 4 to 60 cm H 2 O, were assessed in isolated coronary arterioles in m Lepr db , Lepr db , and Lepr db mice treated with adiponectin. At the end of each experiment, the vessel was relaxed with 100 mol/L SNP to obtain its maximal diameter at 60 cm H 2 O intraluminal pressure. All diameter changes in response to agonists were normalized to the vasodilation in response to 100 mol/L SNP and expressed as a percentage of maximal dilation.
Functional Assessment of Murine Aortas
Aortic rings, 2 mm, were isometrically mounted in a myograph (model 610M); and an optimal passive tension (15 mN) was applied. Aortic rings were precontracted with 1 mol/L phenylephrine. A dose-response curve was obtained by cumulative addition of ACh, 1 nmol/L to 10 mol/L; and SNP, 1 nmol/L to 10 mol/L. Relaxation at each concentration was measured and expressed as the percentage of force generated in response to phenylephrine. 14 
Protein Expression by Western Blot Analyses
Coronary arterioles, 4 to 6 vessels per sample, or aortas were homogenized in lysis buffer (Cellytic MT Mammalian Tissue Lysis/ Extraction Reagent). Protein concentrations were assessed with a kit (BCA Protein Assay Kit), and samples were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes. The levels of TNF-␣, IB␣, phosphorylated IB␣, adiponectin, adiponectin receptor 1 (AdipoR1), adiponectin receptor 2 (AdipoR2), and nuclear factor (NF) B were determined. Signals were visualized by enhanced chemiluminescence and quantified by film imaging (Fuji) software. 13 Housekeeping gene ␤-actin was used as the loading control, and we validated that no significant variation was detected between control and experimental groups and across samples. 13, 14 The relative amounts of protein expression in various groups were quantified and normalized to those of the corresponding m Lepr db control, which were set at 1.0. 13
Immunofluorescence Staining
Immunohistochemistry was used to identify and localize proteins in sections of vessels or myocardial tissue. Hearts or aortas were embedded in optimal cutting temperature and sectioned at 5 m. Slides were incubated with blocking solution (10% donkey serum in PBS). Primary antibodies for adiponectin (goat polyclonal), endothelial cell marker, von Willebrand factor (rabbit polyclonal), smooth muscle ␣-actin (rabbit polyclonal), or fibroblast (rat monoclonal) were used for sequential double immunofluorescence staining. Secondary fluorescent antibodies were either fluorescein isothiocyanate or Texas red conjugated. For negative controls, primary antibodies were replaced with IgG isotype controls at the same concentration. Sections were finally mounted in an antifading agent (Slowfade gold with 4Ј,6-diamidino-2-phenylindole). Slides were observed and analyzed using a fluorescence microscope with a ϫ40 objective (model IX81). 16 
Data Analysis
All data are presented as meanϮSEM except as specifically stated. Statistical comparisons under various treatments were performed with 1-way ANOVA, and intergroup differences were tested with a lysergic acid diethylamide inequality. PϽ0.05 was considered significant. The supplemental data (available online at http://atvb. ahajournals.org) provide further details.
Results
Effects of Adiponectin and Anti-TNF-␣ on Body Weight, Abdominal Girth, Blood Glucose, and Insulin/Insulin Resistance
Body weight and abdominal girth were greater in Lepr db versus m Lepr db . Nonfasting blood glucose level, plasma insulin level, and homeostasis model assessment of insulin resistance (HOMA-IR) were elevated in Lepr db . Adiponectin and anti-TNF-␣ treatment did not affect the described parameters in Lepr db (supplemental Table I ).
Role of Adiponectin in Type 2 Diabetes-Induced Coronary Endothelial Dysfunction
Vasodilation to endothelium-dependent vasodilator ACh was impaired in coronary arterioles of Lepr db ( Figure 1A ). Conversely, adiponectin partially restored ACh-induced vasodilation in Lepr db ( Figure 1A) . Moreover, flow-induced vasodilation was diminished in coronary arterioles of Lepr db but was rescued by adiponectin ( Figure 1B) . In contrast, SNPinduced endothelium-independent vasodilation was similar among m Lepr db , Lepr db , and Lepr db treated with adiponectin ( Figure 1C ).
Role of Adiponectin and TNF-␣ in Type 2 Diabetes-Induced Aortic Endothelial Dysfunction
Endothelium-dependent vasorelaxation in response to ACh was significantly impaired in aortas of Lepr db . Adiponectin and anti-TNF-␣ partially restored impaired vasorelaxation ( Figure 2A and C and supplemental Table II Table II) .
Reciprocal Association Between Adiponectin and TNF-␣ in Coronary Arterioles and Aortas of Diabetic Mice
Protein expressions of adiponectin and TNF-␣ from isolated coronary arterioles and aortas were analyzed in m Lepr db , Lepr db , and Lepr db mice treated with anti-TNF-␣ or adi- ponectin. Western blot analysis ( Figure 3 ) revealed that anti-TNF-␣ markedly increased adiponectin expression, whereas adiponectin reduced TNF-␣ expression in both coronary arterioles and aortas of diabetic mice. mRNA expression of TNF-␣ was consistent with protein expression, but mRNA expression of adiponectin showed no difference among groups (supplemental Figure I ).
Cellular Source of Adiponectin Expression in Type 2 Diabetes
Immunostaining showed that adiponectin protein expression (red) was present in endothelial cells but not in vascular smooth muscle cells in both coronary microvessels ( Figure 4 ) and aortas (supplemental Figure II) . Adiponectin staining was absent in APN Ϫ/Ϫ mice, which validated the specificity of staining (supplemental Figure III) .
AdipoR Expression in Coronary Arterioles and Aortas of Diabetic Mice
AdipoR1 protein expression was not significantly different between m Lepr db and Lepr db in both coronary arterioles and aortas ( Figure 5A and B) , whereas AdipoR2 protein expression was greatly decreased in Lepr db coronary arterioles and aortas ( Figure 5C and D).
Adiponectin and TNF-␣ Signaling Converged on NFB to Reciprocally Regulate Their Expression
In both coronary arterioles and aortas, IB␣ (inhibitor of NFB) expression was decreased in Lepr db ( Figure 6A and D), whereas phosphorylated IB␣ was greatly elevated (Figure 6B and E). Both adiponectin and anti-TNF-␣ inhibited IB␣ phosphorylation ( Figure 6B and E) without affecting total IB␣ expression ( Figure 6A and D) . NFB p65 protein expression was significantly higher in Lepr db . Adiponectin and anti-TNF-␣ decreased NFB protein expression ( Figure  6C and F).
Discussion
To our knowledge, this is the first in vivo evidence for a reciprocal regulation occurring between adiponectin and TNF-␣ in microcirculation and macrocirculation in type 2 diabetic mice. The circulatory protein adiponectin protects against diabetes-induced coronary arteriolar and aortic vascular dysfunction; this protection involves, at least in part, the downregulation of TNF-␣. Furthermore, inhibition of TNF-␣ is associated with upregulation of adiponectin in microvessels and macrovessels. Taken together, these data suggest that the reciprocal suppression of adiponectin and TNF-␣ functionally contributes to the regulation of diabetes-associated vascular dysfunction.
Vascular Effects of TNF-␣ and Adiponectin in Type 2 Diabetes
TNF-␣ and adiponectin are important adipose-derived factors. TNF-␣ is a key proinflammatory cytokine mainly secreted by nonfat cells in adipose tissue. 17 It was previously demonstrated that TNF-␣ contributed to endothelial dysfunc- tion in type 2 diabetes by inducing activation of NAD(P)H oxidase and production of reactive oxygen species in both aortas and coronary microcirculation. 13, 14, 18 Adiponectin is a relatively abundant plasma protein specifically secreted by adipocytes. Adiponectin exists in the circulation as a fulllength protein and as a putative proteolytic cleavage fragment consisting of the globular C-terminal domain (gAd), which may have enhanced potency. 19, 20 The biological activities of gAd are controversial because of its proinflammatory effects in cardiac fibroblasts, 21 but it appears that globular adiponectin is significantly more potent in reversing insulin resistance and exerts vascular protective effects by enhancing NO availability in endothelial cells. 22, 23 gAd incubation, 2 mg/ mL, for 2 hours improved endothelium-dependent relaxation and total production of NO as a result of enhanced eNOS activity. 24 In Lepr db mice, serum adiponectin levels are significantly reduced compared with those in m Lepr db (supplemental Table I ). By treating the mice with recombinant globular adiponectin, we found that long-term adiponectin administration rescues both coronary microvascular and aortic macrovascular dysfunction in type 2 diabetic mice (Figures 1 and 2) . This vasoprotection by adiponectin may be partly through the direct vascular effects of stimulating endothelial NO production and ameliorating oxidative stress based on previous studies using APN Ϫ/Ϫ mice. In APN
, ACh-induced vasodilation in aortas was impaired, accompanied by increased superoxide and peroxynitrite production. eNOS expression was conserved in APN Ϫ/Ϫ mice, but NO production and eNOS phosphorylation were significantly reduced. 25 Adiponectin also causes endothelium-independent vasodilation by opening voltage-gated K channels. 26 However, the endotheliumindependent vasodilatory effects of adiponectin do not represent a common pathway for the regulation of vascular dysfunction in type 2 diabetic mice because SNP-induced vasodilation is similar among m Lepr db , untreated diabetic mice, diabetic mice treated with adiponectin, or the neutralizing antibody to TNF␣ (anti-TNF-␣) ( Figure 1C and Figure 2B and D).
Reciprocal Regulation Between Adiponectin and TNF-␣
The reciprocal regulation between adiponectin and TNF-␣ has been studied in various tissues and cells. Adiponectin suppresses lipopolysaccharide-stimulated TNF-␣ production in cultured cardiac myocytes and macrophages, 7,27,28 whereas adiponectin deficiency leads to an increase in circulating TNF-␣ in mouse models. 29 TNF-␣ also has a regulatory effect on adiponectin. By incubating human visceral adipose tissue with TNF-␣ in vitro, the mRNA and protein expressions of adiponectin were significantly reduced. 30 However, there are no in vivo studies examining the reciprocal association between adiponectin and TNF-␣ in the vasculature. Also, the role of this reciprocal regulation in the pathogenesis of diabetes-induced microvascular and macrovascular dysfunction has not been investigated. Our results suggest that anti-TNF-␣ treatment upregulates adiponectin expression; however, adiponectin treatment inhibits TNF-␣ expression in coronary arterioles and aortas of diabetic mice ( Figure 3) . Thus, adiponectin and TNF-␣ not only exert vascular effects independently by affecting vascular NO bioavailability and oxidative stress 13, 14, 25 but also act interactively to participate in the complex regulation of their combined vascular expression in type 2 diabetes.
Adiponectin and AdipoR Expression in Coronary Microvessels and Aortas
Two receptor forms have been cloned for adiponectin, and the receptors have unique distributions and affinities for the molecular forms of adiponectin. AdipoR1 is a high-affinity receptor for gAd with low affinity for full-length protein, and AdipoR2 has intermediate affinity for both forms of adiponectin. 3 Interestingly, AdipoR1 is abundantly expressed in skeletal muscle and moderately expressed in other tissues, whereas AdipoR2 is predominantly expressed in the liver. 20, 31, 32 Aortic endothelial cells express both adiponectin isoforms but appear to preferentially express mRNA of AdipoR1. 33 In human umbilical vein endothelial cells, globular adiponectin-induced phosphorylation of eNOS at serine 1177 and NO production 22 were abrogated when expressions of AdipoR1 and AdipoR2 were simultaneously suppressed. 34 Overexpression of AdipoR1 and AdipoR2 in human umbilical vein endothelial cells significantly enhanced the suppressive effect of an otherwise symptomless dose of globular adiponectin on TNF-␣-induced intercellular adhesion molecule 1 expression and NFB activation, suggesting the involvement of AdipoRs in adiponectin-induced vasoprotection against the proinflammatory effects of TNF-␣. 35 To our knowledge, this study provides the first in vivo documentation that AdipoR1 expression is similar between control and diabetic mice but AdipoR2 expression is significantly reduced in both coronary arterioles and aortas in diabetic mice ( Figure 5 ). Furthermore, AdipoR2 expression in aortas of diabetic mice is only 25% of that in aortas of m Lepr db , but AdipoR2 expression in coronary arterioles of diabetic mice is approximately 47% of that in coronary vessels of m Lepr db . The mechanisms accounting for the reduced AdipoR2, but not AdipoR1, expression in diabetic mice vasculature, and the possible differences in AdipoR2 expression between vascular beds, remain unknown. However, our results suggest that, in addition to the reduced circulating level of adiponectin in diabetic mice (supplemental Table I ), suppressed AdipoR2 expression and the receptor-mediated response may also contribute to the impaired adiponectin-mediated vascular protective effects. Moreover, an increased serum TNF-␣ level (supplemental Table I ) and TNF-␣ receptor 1 expression in diabetic mice synergistically exacerbated the detrimental effects of TNF-␣ on vascular function. 36 Thus, in addition to modulating adiponectin and TNF-␣ production and circulatory levels, treatments mediating AdipoR2 and TNF-␣ receptor 1 expression may have potential therapeutic applications for vascular complications associated with the metabolic syndrome and diabetes.
Adiponectin and TNF-␣ Converge on NFB to Regulate Their Reciprocal Suppression
Adiponectin-mediated suppression of TNF-␣ expression and inflammatory responses by the inhibition of NFB signaling functionally contribute to the beneficial actions of adiponectin. 37, 38 Full-length protein suppresses TNF-␣-induced inflammatory changes in human aortic endothelial cells by blocking IB␣ phosphorylation and NFB activation without affecting TNF-␣-mediated activation of c-JUN N-terminal kinase, p38, and protein kinase B (Akt). 38 gAd has attenuated lipopolysaccharide-stimulated TNF-␣ production in macrophages by suppression of NFB activation. 37 TNF-␣ per se suppresses adiponectin secretion in 3T3-L1 adipocytes; this suppression was reversed by an IB kinase-␤ inhibitor, IMD-0354. 39 These data suggest that NFB signaling may act as a pivot for a reciprocal association between adiponectin and TNF-␣.
Our studies demonstrate this pivotal role of NFB signaling in the reciprocal association between adiponectin and TNF-␣ in both coronary microcirculation and aortas in the type 2 diabetic murine model. The results reveal that adiponectin and anti-TNF-␣ treatment remarkably inhibit IB␣ phosphorylation and NFB expression in coronary arterioles and aortas of Lepr db without affecting total IB␣ expression ( Figure 6 ). Therefore, adiponectin and TNF-␣ may converge on NFB signaling to reciprocally regulate their expression and function in coronary microvessels and aortas in type 2 diabetic mice. In conclusion, although TNF-␣ is a key adipokine promoting endothelial dysfunction, adiponectin may prevent vascular injury. This paradigm for adipokine regulation of endothelial function may have important therapeutic implications in diabetes-associated vascular complications.
